H
Highlight Therapeutics
A private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology
About Highlight Therapeutics
Highlight Therapeutics is a private, clinical-stage biotechnology company focused on developing RNA-based immuno-oncology therapies. The company's main program is BO-112, a synthetic double-stranded RNA that mimics a viral infection, which is designed to be injected directly into a tumor to activate the innate immune system and enhance the efficacy of other cancer treatments, including checkpoint inhibitors.
The company's business model is centered on the research and development of these novel cancer therapies. Highlight Therapeutics aims to partner with larger pharmaceutical companies for late-stage development, commercialization, and marketing of its products. The company's target market is the oncology sector, specifically focusing on patients with solid tumors who are not responding to or have relapsed after treatment with checkpoint inhibitors. By targeting this patient population, the company is addressing a significant unmet medical need in the cancer treatment landscape.
Highlight Therapeutics was founded in 2010 and is based in Paterna, Spain. The company has raised Series B funding and is actively advancing its clinical programs to bring its innovative therapies to market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Paterna, Spain
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 79.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, Woman Founder, Seal of Excellence EC, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VC✓Equity / VC | Sep 2025 | $17M | — | Buenavista Equity Partners | ↗ |
| LATE VC✓Equity / VC | Feb 2021 | $25M | $99M | CDTI Innvierte · Columbus Venture Partners · Advent Life Sciences | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Highlight Therapeutics is 1K monthly website visits, up 185.7% over the last three months. Highlight Therapeutics's team declined 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
Columbus Venture Partners
Advent Life Sciences
CDTI Innvierte
Buenavista Equity Partners
Other known investors4 additional known investors
Realiza Business Angels
CNIO
Droia Oncology Ventures
Keith Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Highlight Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Highlight Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.